Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | KHK | P50053 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12113672 | 0.87 | ADORA2A (0.33) | ADORA2AADORA1 | |
| SCHEMBL16478438 | 0.77 | ADORA2A (0.36) | ADORA2AADORA1 | |
| SCHEMBL10171941 | 0.77 | ADORA2A (0.36) | ADORA2AADORA1 | |
| SCHEMBL10139171 | 0.77 | DYRK1A (0.32) | ADORA2AADORA1 | |
| SCHEMBL2748015 | 0.76 | DYRK1A (0.46) | ADORA2AADORA1 | |
| SCHEMBL24996409 | 0.73 | TYK2 (0.34) | — | |
| SCHEMBL12397282 | 0.73 | DYRK1A (0.33) | ADORA2AADORA1 | |
| SCHEMBL19820344 | 0.71 | JAK2 (0.30) | — | |
| SCHEMBL12510082 | 0.70 | CDK1 (0.39) | ADORA2A | |
| SCHEMBL24995899 | 0.70 | REN (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | EGFR, ERBB2, BRCA1 | ADORA2A 2554/4885ADORA1 3516/4885KHK 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.